Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Patrick K. Reville"'
Autor:
Elisabeth Paietta, Fangxin Hong, Brad S. Kahl, Kyung Mann Kim, Vaishalee P. Kenkre, Bartosz Grzywacz, Erik A. Ranheim, Patrick K. Reville, Lakeesha Carmichael, Eneida A. Mendonça, Amy K. Erbe, Wei Wang, Paul M. Sondel, Sandra J. Horning, Anna Hoefges, Yiqiang Song, Songwon Seo, Jeffrey S. Miller, Randy D. Gascoyne, Jacquelyn A. Hank
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Background The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-
Autor:
Susan L. Cohn, Stephen D. Gillies, Ralph A. Reisfeld, Julie R. Park, Wei Wang, Alice L. Yu, M. Fevzi Ozkaynak, Patrick K. Reville, Jacquelyn A. Hank, Michael D. Hogarty, Wendy B. London, Andrew L. Gilman, Paul M. Sondel, Yiqiang Song, Arlene Naranjo, Lakeesha Carmichael, Mitchell B. Diccianni, Amy K. Erbe, John M. Maris, Katherine K. Matthay, Dustin Hess, KyungMann Kim, Eneida A. Mendonça
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 1
Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy re
Autor:
Lakeesha Carmichael, Amy K. Erbe, Paul M. Sondel, Michael D. Hogarty, Julie R. Park, Wei Wang, Patrick K. Reville, Mitchell B. Diccianni, Wendy B. London, Arlene Naranjo, Jacquelyn A. Hank, KyungMann Kim, Alice L. Yu
Publikováno v:
Cancer Research. 77:LB-048
Introduction: High-risk neuroblastoma (NBL) patients (pts) enrolled in a COG Phase 3 clinical trial (ANBL0032) were randomized to isotretinoin (RA) alone or Immunotherapy: dinutuximab (anti-GD2 mAb) + IL2 + GMCSF + RA (Yu et al., NEJM, 2010). Dinutux